AbbVie Receives CHMP Positive Opinion for Risankizumab (SKYRIZI®) for the Treatment of Adults with Active Psoriatic Arthritis in the European Union (EU)PRNewsWire • 10/15/21
AbbVie Inc.: Dissect Its Growth Sustainability And Capital Allocation Like BuffettSeeking Alpha • 10/12/21
AbbVie (ABBV) Dips More Than Broader Markets: What You Should KnowZacks Investment Research • 10/11/21
Allergan Aesthetics Launches Series of Initiatives to Support Breast Cancer AwarenessPRNewsWire • 10/11/21
AbbVie's Upadacitinib (RINVOQ®) Met Primary and Most Ranked Secondary Endpoints in Phase 3 Study for Non-Radiographic Axial SpondyloarthritisPRNewsWire • 10/07/21
AbbVie's RINVOQ® (upadacitinib) Met Primary and All Ranked Secondary Endpoints in Phase 3 Study in Ankylosing SpondylitisPRNewsWire • 10/07/21
AbbVie to Showcase New Data at the United European Gastroenterology (UEG) Week Virtual 2021PRNewsWire • 10/02/21